Investigational drug · Phase 2
GSK4532990
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-alcoholic Fatty Liver Disease, Liver Diseases, Alcoholic, Nonalcoholic Fatty Liver Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
3
Any phase or sponsor naming "GSK4532990"
First trial start
2023
Jan 2, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK4532990", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-alcoholic Fatty Liver Disease
- Liver Diseases, Alcoholic
- Nonalcoholic Fatty Liver Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK4532990" as an intervention, largest first.
GlaxoSmithKlineGSK (GSK)
NCT06613698 · 350 participants (planned) · Start Sep 27, 2024 · Primary completion Nov 26, 2027
Drug: GSK4532990; Placebo · For: Liver Diseases, Alcoholic
Sites: Chandler, Arizona; Phoenix, Arizona; Tucson, Arizona · 150 sites in all
- Phase 2b Study of GSK4532990 in Adults With NASHPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05583344 · 284 participants · Start Jan 2, 2023 · Primary completion Jan 31, 2026
Drug: GSK4532990; Placebo · For: Nonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver Disease
Sites: Homewood, Alabama; Chandler, Arizona; Mesa, Arizona · 171 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06104319 · 61 participants · Start Jan 22, 2024 · Primary completion Sep 23, 2025
Drug: GSK4532990 · For: Non-alcoholic Fatty Liver Disease
Sites: Chula Vista, California; Montclair, California; San Diego, California · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-alcoholic Fatty Liver Disease
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
- HU6Phase 22 trials
Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- MN-001Phase 21 trial
MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.